Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
Year: 2020
Type: article
Abstract: This review reflects the presentations and discussion at the 14th post-American Society of Hematology (ASH) International Workshop on Chronic Myeloproliferative Malignancies, which took place on the December 10 and 11, 2019, immediately after the 61st ASH Annual Meeting in Orlando, Florida. Rather than present a resume of the proceedings, we address some of the topical translational science research and clinically relevant topics in detail. We consider how recent studies using single-cell genomics and other molecular methods reveal novel aspects of hematopoiesis which in turn raise the possibility of new therapeutic approaches for patients with myeloproliferative neoplasms (MPNs). We discuss how alternative therapies could benefit patients with chronic myeloid leukemia who develop BCR-ABL1 mutant subclones following ABL1-tyrosine kinase inhibitor therapy. In MPNs, we focus on efforts beyond JAK-STAT and the merits of integrating activin receptor ligand traps, interferon-α, and allografting in the current treatment algorithm for patients with myelofibrosis.
Source: Hematological Oncology
DOI: 10.1002/hon.2771
Institutions: Tufts University, Tufts Medical Center, The University of Texas MD Anderson Cancer Center, University of Oxford, MRC Weatherall Institute of Molecular Medicine, Fred Hutch Cancer Center, Université Paris Cité, Hôpital Saint-Louis, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Johns Hopkins Hospital, University of Kansas, Augusta University, Mays Cancer Center at UT Health San Antonio, University of Turin, University of California, Irvine
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
OpenAlex ID: W3038008221